Significant time until catheter occlusion alerts in currently marketed insulin pumps at two basal rates

Diabetes Technology and Therapeutics

Volumn 14, Issue 5, 2012, Pages 447-448

  Van Bon, Arianne C ^a   Dragt, Dorien ^a   DeVries, J Hans ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; CATHETER OCCLUSION; COMPARATIVE STUDY; DEVICE SAFETY; DISEASE DURATION; HUMAN; INFUSION RATE; INSULIN INFUSION; INSULIN PUMP; LETTER; MARKETING; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

BLOOD GLUCOSE; CATHETERS, INDWELLING; DIABETES MELLITUS, TYPE 1; EQUIPMENT FAILURE; FEMALE; HUMANS; INFUSION PUMPS, IMPLANTABLE; INSULIN; INSULIN INFUSION SYSTEMS; MALE; TIME FACTORS;

EID: 84860590392     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0259     Document Type: Letter

References (2)

1. Raskin P, Holcombe JH, Tamborlane WV, Malone JI, Strowig S, Ahern JA, Lavent F: A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications 2001;15:295-300.
2. van Bon AC, Bode BW, Langeron C, DeVries JH, Charpentier G: Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther 2011;13: 607-614.